Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 13/20 | 0.71 |
| ▸ | JAK3 | P52333 | 9/20 | 0.71 |
| ▸ | PTK2 | Q05397 | 9/20 | 0.71 |
| ▸ | JAK1 | P23458 | 3/20 | 0.59 |
| ▸ | CFTR | P13569 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | AXL | P30530 | 1/20 | 0.49 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13072884 | 0.92 | JAK2 (0.60) | JAK2JAK3PTK2JAK1SRC | |
| SCHEMBL13072981 | 0.92 | JAK2 (0.84) | JAK2JAK3PTK2JAK1SRC | |
| SCHEMBL13073193 | 0.91 | JAK2 (0.82) | JAK2JAK3PTK2JAK1SRC | |
| SCHEMBL13072784 | 0.88 | JAK2 (0.77) | JAK2JAK3PTK2JAK1AXL | |
| SCHEMBL3597688 | 0.87 | JAK2 (0.76) | JAK2JAK3PTK2JAK1SRC | |
| SCHEMBL3214576 | 0.87 | JAK2 (0.63) | JAK2JAK3PTK2JAK1 | |
| SCHEMBL13073432 | 0.86 | JAK2 (0.59) | JAK2JAK3PTK2JAK1 | |
| SCHEMBL13032972 | 0.86 | JAK2 (0.77) | JAK2JAK3PTK2JAK1SRC | |
| SCHEMBL13072803 | 0.85 | JAK2 (0.73) | JAK2JAK3PTK2JAK1AXL | |
| SCHEMBL3216367 | 0.85 | JAK2 (0.82) | JAK2JAK3PTK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771362-B2 | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-09-26 | — | — | US | disclosed |
| US-20170066762-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-03-09 | — | — | US | disclosed |
| US-9394301-B2 | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-07-19 | — | — | US | disclosed |
| US-20150246915-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-09-03 | — | — | US | disclosed |
| US-9012633-B2 | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-04-21 | — | — | US | disclosed |
| EP-2217578-B9 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE | CANCER REC TECH LTD (GB) | 2014-09-10 | — | — | EP | disclosed |
| US-20140155594-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-06-05 | — | — | US | disclosed |
| US-8431596-B2 | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-04-30 | — | — | US | disclosed |
| US-20100298339-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| WO-2009047514-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246915-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | AXL, TYRO3, FLT3 | JAK2 16/4885JAK3 40/4885PTK2 35/4885 |
| US-20100298339-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | AXL, TYRO3, FLT3 | JAK2 16/4885JAK3 40/4885PTK2 35/4885 |
| US-20140155594-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | AXL, TYRO3, FLT3 | JAK2 16/4885JAK3 40/4885PTK2 35/4885 |
| US-20170066762-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | AXL, TYRO3, FLT3 | JAK2 16/4885JAK3 40/4885PTK2 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.